Only 38% of Americans say that they are either very confident or somewhat confident that the administration’s plan will result in paying less for their prescription drugs.
When the Trump administration unveiled the “American Patients First” blueprint to lower drug prices in May 2018, it indicated that its priorities were improving competition, improving negotiation, lowering list prices for drugs, and reducing out-of-pocket spending for patients. At the time, stakeholders met the plan with cautious optimism.
However, according to a recent poll conducted by the Kaiser Family Foundation, only 38% of Americans say that they are either very confident or somewhat confident that the administration’s plan will result in paying less for their prescription drugs.
Click to read more about the drug pricing blueprint.
Republicans had the greatest level of confidence in the drug pricing plan, with 40% reporting that they were very confident and 43% reporting that they were somewhat confident that they would see lower prices for their medicines. By contrast, just 4% of Democrats were very confident, and 25% were somewhat confident, that they would experience a reduction in the prices that they pay for their drugs.
Furthermore, a majority of Americans (55%) said that the President’s strategy of publicly criticizing drug companies and calling for them to reduce the cost of their drugs was likely to be not at all effective or not too effective.
Increases in the amount that individuals pay for their healthcare are front-of-mind for a majority of Americans; 58% of respondents said they were “very concerned,” and 30% said they were “somewhat concerned,” about growing costs to individuals.
Americans overwhelmingly agree that pharmaceutical companies’ profits are a major reason behind continually rising healthcare costs; 78% of respondents cited drug company profits as a major reason for growing healthcare costs. Respondents also cited fraud and waste in the healthcare system (71%), overcharging by hospitals (71%), and excessive profits for insurance companies (70%) as the other major reasons for cost growth.
Kaiser’s poll also revealed that healthcare costs are a key issue for voters as the nation approaches the 2018 elections; when voters who said that they want candidates to talk about healthcare are asked which issue they most want to hear discussed, 27% of all voters mention the cost of healthcare. Cost was mentioned 3 times more frequently than any other healthcare issue, including universal coverage, increasing access, or Medicare concerns.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.